Lipella Pharmaceuticals Delisted from Nasdaq, Plans to Relist on National Exchange

LIPELLA PHARMACEUTICALS INC.

Delisted from Nasdaq effective June 19, 2025 due to non-compliance with Listing Rules 5100, 5635, and 5640 regarding private placement transactions.
Common stock now quoted on OTC Pink Market under symbol LIPO; company remains fully reporting with SEC.
CEO Jonathan Kaufman issued stockholder letter detailing plans to submit initial listing application to another national exchange.
Clinical programs LP-310 (oral lichen planus) and LP-10 (hemorrhagic cystitis) continue unaffected; final LP-310 Phase 2a data expected H2 2025.
Company states delisting was not due to financial instability and maintains sufficient capital for development programs.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.